Table 1. Suggested biochemical and radiological screening in individuals at high risk of developing MEN1 associated PNETs.

Pancreatic NET	Age to begin (year)	Biochemical test (plasma or serum) annually	Imaging test (time interval)
Gastrinoma	20	Gastrin (gastric pH)	None
Insulinoma	5	Fasting glucose, insulin	None
Other pancreatic NET	<10	Chromogranin A, pancreatic polypeptide, glucagon, VIP	MRI, CT, or EUS (annually)

MEN1, multiple endocrine neoplasia type 1; PNETs, pancreatic neuroendocrine tumors; EUS, endoscopic ultrasound; VIP, vasoactive intestinal peptide. Adapted from Thakker et al. (4).